Abstract

In the first trial comparing abciximab with tirofiban (TARGET), abciximab was superior in preventing periprocedural myonecrosis during planned coronary

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call